查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1285898

作用于RAS的药剂市场（药物类别：ACE抑制剂、血管紧张素II受体阻断剂[ARB]、肾素抑制剂、醛固酮拮抗剂及其他） - 2023-2031年全球行业分析、规模、份额、增长、趋势和预测

RAS-acting Agents Market (Drug Class: ACE Inhibitors, Angiotensin II Receptor Blockers [ARBs], Renin Inhibitors, Aldosterone Antagonists, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 209 Pages | 商品交期: 2-10个工作天内

价格

RAS-反应剂市场 - 报告范围

TMR关于全球RAS反应剂市场的报告研究了过去以及当前的增长趋势和机会，以获得对2023年至2031年预测期间市场指标的宝贵见解。报告提供了2017-2031年期间全球RAS-反应剂市场的收入，考虑到2023年为基准年，2031年为预测年。报告还提供了2023年至2031年全球RAS-反应剂市场的复合年增长率（CAGR %）。

该报告是在广泛的研究后编写的。一级研究涉及大部分的研究工作，其中分析师与关键的意见领袖、行业领袖和意见制造者进行了访谈。二级研究包括参考主要参与者的产品资料、年度报告、新闻稿和相关文件，以了解等离子体材料市场。

该报告深入研究了全球等离子体材料市场的竞争格局。已经确定了在全球RAS-acting Agents市场上运作的主要参与者，并从各种属性方面对其中的每一个参与者进行了分析。公司概况、财务状况、最近的发展和SWOT是本报告对全球RAS-反应剂市场参与者的属性描述。

目录

第一章：前言

  • 市场定义和范围
  • 市场细分
  • 主要研究目标
  • 研究重点

第二章：假设和研究方法

第三章：执行摘要：全球市场

第四章：市场概述

  • 简介
    • 细分市场的定义
    • 行业演变/发展
  • 市场概况
  • 市场动态
    • 驱动力
    • 限制因素
    • 机会
  • 2017-2031年全球市场分析与预测

第5章：关键洞察力

  • 技术进步
  • 全球主要国家的疾病流行率和发病率
  • 关键的行业事件
  • COVID-19的影响分析

第六章：全球市场分析和预测：按药物类别分类

  • 介绍和定义
  • 主要研究结果/发展
  • 市场价值预测：按药物类别，2017-2031年
    • ACE抑制剂
    • 血管紧张素II受体阻断剂（ARBs）
    • 肾素抑制剂
    • 醛固酮拮抗剂
    • 其他（利尿剂）
  • 市场吸引力分析：按药物类别

第7章 ：全球市场分析和预测：按适应症分类

  • 介绍和定义
  • 主要研究结果/发展
  • 市场价值预测：按适应症分类，2017-2031年
    • 高血压
    • 心力衰竭
    • 慢性肾脏病
    • 糖尿病肾病
    • 冠状动脉疾病
  • 市场吸引力分析：按适应症

第八章：全球市场分析与预测：按分销渠道分类

  • 介绍和定义
  • 主要研究结果/发展
  • 市场价值预测：按分销渠道分类，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场吸引力分析：按分销渠道分类

第九章：全球市场分析与预测：按地区分类

  • 主要发现
  • 市场价值预测：按地区划分，2017-2031年
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第十章：北美市场分析与预测

  • 简介
    • 主要研究结果
  • 市场价值预测：按药物类别，2017-2031年
    • ACE抑制剂
    • 血管紧张素II受体阻断剂（ARBs）
    • 肾素抑制剂
    • 醛固酮拮抗剂
    • 其他（利尿剂）
  • 市场价值预测：按适应症，2017-2031年
    • 高血压
    • 心力衰竭
    • 慢性肾脏病
    • 糖尿病肾病
    • 冠状动脉疾病
  • 市场价值预测：按分销渠道，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家划分，2017-2031年
    • 美国
    • 加拿大
  • 市场吸引力分析
    • 按药物类别
    • 按适应症分类
    • 按销售渠道分类
    • 按国家分类

第11章 ：欧洲市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按药物类别，2017-2031年
    • ACE抑制剂
    • 血管紧张素II受体阻断剂（ARBs）
    • 肾素抑制剂
    • 醛固酮拮抗剂
    • 其他（利尿剂）
  • 市场价值预测：按适应症，2017-2031年
    • 高血压
    • 心力衰竭
    • 慢性肾脏病
    • 糖尿病肾病
    • 冠状动脉疾病
  • 市场价值预测：按分销渠道，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家/次区域划分，2017-2031年
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 市场吸引力分析
    • 按药物类别
    • 按适应症分类
    • 按分销渠道分类
    • 按国家/次区域分类

第十二章 ：亚太地区市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按药物类别，2017-2031年
    • ACE抑制剂
    • 血管紧张素II受体阻断剂（ARBs）
    • 肾素抑制剂
    • 醛固酮拮抗剂
    • 其他（利尿剂）
  • 市场价值预测：按适应症，2017-2031年
    • 高血压
    • 心力衰竭
    • 慢性肾脏病
    • 糖尿病肾病
    • 冠状动脉疾病
  • 市场价值预测：按分销渠道，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家/次区域划分，2017-2031年
    • 中国
    • 日本
    • 印度
    • 澳大利亚和新西兰
    • 亚太其他地区
  • 市场吸引力分析
    • 按药物类别
    • 按适应症分类
    • 按分销渠道
    • 按国家/次区域分类

第13章 ：拉丁美洲（LATAM）市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按药物类别，2017-2031年
    • ACE抑制剂
    • 血管紧张素II受体阻断剂（ARBs）
    • 肾素抑制剂
    • 醛固酮拮抗剂
    • 其他（利尿剂）
  • 市场价值预测：按适应症，2017-2031年
    • 高血压
    • 心力衰竭
    • 慢性肾脏病
    • 糖尿病肾病
    • 冠状动脉疾病
  • 市场价值预测：按分销渠道，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家/次区域划分，2017-2031年
    • 巴西
    • 墨西哥
    • 拉美其他地区
  • 市场吸引力分析
    • 按药物类别
    • 按适应症分类
    • 按分销渠道分类
    • 按国家/次区域分类

第十四章：中东和非洲市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按药物类别，2017-2031年
    • ACE抑制剂
    • 血管紧张素II受体阻断剂（ARBs）
    • 肾素抑制剂
    • 醛固酮拮抗剂
    • 其他（利尿剂）
  • 市场价值预测：按适应症，2017-2031年
    • 高血压
    • 心力衰竭
    • 慢性肾脏病
    • 糖尿病肾病
    • 冠状动脉疾病
  • 市场价值预测：按分销渠道，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家/次区域划分，2017-2031年
    • 海湾合作委员会国家
    • 南非
    • 中东和非洲其他地区
  • 市场吸引力分析
    • 按药物类别
    • 按适应症分类
    • 按分销渠道分类
    • 按国家/次区域分类

第十五章 ：竞争格局

  • 市场参与者 - 竞争矩阵（按公司层级和规模）。
  • 市场份额分析：按公司分类 (2022)
  • 公司简介
    • Novartis AG
    • Pfizer, Inc.
    • AstraZeneca plc
    • Merck & Co., Inc.
    • Sanofi S.A.
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company, Limited
    • Takeda Pharmaceutical Company Limited
    • Boehringer Ingelheim GmbH
    • Johnson & Johnson
Product Code: TMRGL85539

RAS-acting Agents Market - Scope of Report

TMR's report on the global RAS-acting Agents Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global RAS-acting Agents Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global RAS-acting Agents Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the RAS-acting Agents market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global RAS-acting Agents market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global RAS-acting Agents market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global RAS-acting Agents market.

The report delves into the competitive landscape of the global RAS-acting Agents market. Key players operating in the global RAS-acting Agents Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global RAS-acting Agents Market profiled in this report.

Key Questions Answered in Global RAS-acting Agents Market Report:

  • What is the sales/revenue generated by RAS-acting Agents across all regions during the forecast period?
  • What are the opportunities in the global RAS-acting Agents market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

RAS-acting Agents Market - Research Objectives and Research Approach

The comprehensive report on the global RAS-acting Agents Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global RAS-acting Agents Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global RAS-acting Agents market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global RAS-acting Agents Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global RAS-acting Agents Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
  • 5.3. Key Industry Events
  • 5.4. COVID-19 Impact Analysis

6. Global RAS-acting Agents Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. ACE inhibitors
    • 6.3.2. Angiotensin II Receptor Blockers (ARBs)
    • 6.3.3. Renin Inhibitors
    • 6.3.4. Aldosterone Antagonists
    • 6.3.5. Others (diuretics)
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global RAS-acting Agents Market Analysis and Forecast, by Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Indication, 2017-2031
    • 7.3.1. Hypertension
    • 7.3.2. Heart Failure
    • 7.3.3. Chronic Kidney Disease
    • 7.3.4. Diabetic Nephropathy
    • 7.3.5. Coronary Artery Disease
  • 7.4. Market Attractiveness Analysis, by Indication

8. Global RAS-acting Agents Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global RAS-acting Agents Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America RAS-acting Agents Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. ACE inhibitors
    • 10.2.2. Angiotensin II Receptor Blockers (ARBs)
    • 10.2.3. Renin Inhibitors
    • 10.2.4. Aldosterone Antagonists
    • 10.2.5. Others (diuretics)
  • 10.3. Market Value Forecast, by Indication, 2017-2031
    • 10.3.1. Hypertension
    • 10.3.2. Heart Failure
    • 10.3.3. Chronic Kidney Disease
    • 10.3.4. Diabetic Nephropathy
    • 10.3.5. Coronary Artery Disease
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Indication
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe RAS-acting Agents Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. ACE inhibitors
    • 11.2.2. Angiotensin II Receptor Blockers (ARBs)
    • 11.2.3. Renin Inhibitors
    • 11.2.4. Aldosterone Antagonists
    • 11.2.5. Others (diuretics)
  • 11.3. Market Value Forecast, by Indication, 2017-2031
    • 11.3.1. Hypertension
    • 11.3.2. Heart Failure
    • 11.3.3. Chronic Kidney Disease
    • 11.3.4. Diabetic Nephropathy
    • 11.3.5. Coronary Artery Disease
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Indication
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific RAS-acting Agents Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. ACE inhibitors
    • 12.2.2. Angiotensin II Receptor Blockers (ARBs)
    • 12.2.3. Renin Inhibitors
    • 12.2.4. Aldosterone Antagonists
    • 12.2.5. Others (diuretics)
  • 12.3. Market Value Forecast, by Indication, 2017-2031
    • 12.3.1. Hypertension
    • 12.3.2. Heart Failure
    • 12.3.3. Chronic Kidney Disease
    • 12.3.4. Diabetic Nephropathy
    • 12.3.5. Coronary Artery Disease
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Indication
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America (LATAM) RAS-acting Agents Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. ACE inhibitors
    • 13.2.2. Angiotensin II Receptor Blockers (ARBs)
    • 13.2.3. Renin Inhibitors
    • 13.2.4. Aldosterone Antagonists
    • 13.2.5. Others (diuretics)
  • 13.3. Market Value Forecast, by Indication, 2017-2031
    • 13.3.1. Hypertension
    • 13.3.2. Heart Failure
    • 13.3.3. Chronic Kidney Disease
    • 13.3.4. Diabetic Nephropathy
    • 13.3.5. Coronary Artery Disease
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of LATAM
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Indication
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa RAS-acting Agents Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. ACE inhibitors
    • 14.2.2. Angiotensin II Receptor Blockers (ARBs)
    • 14.2.3. Renin Inhibitors
    • 14.2.4. Aldosterone Antagonists
    • 14.2.5. Others (diuretics)
  • 14.3. Market Value Forecast, by Indication, 2017-2031
    • 14.3.1. Hypertension
    • 14.3.2. Heart Failure
    • 14.3.3. Chronic Kidney Disease
    • 14.3.4. Diabetic Nephropathy
    • 14.3.5. Coronary Artery Disease
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Indication
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Novartis AG
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Drug Class Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Pfizer, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Drug Class Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. AstraZeneca plc
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Drug Class Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Merck & Co., Inc.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Drug Class Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Sanofi S.A.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Drug Class Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Bristol-Myers Squibb Company
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Drug Class Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Daiichi Sankyo Company, Limited
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Drug Class Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Takeda Pharmaceutical Company Limited
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Drug Class Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Boehringer Ingelheim GmbH
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Drug Class Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Johnson & Johnson
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Drug Class Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview

List of Tables

  • Table 01: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 03: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 07: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 08: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 11: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 12: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 15: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 16: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 19: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 20: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 23: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 24: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global RAS-acting Agents Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
  • Figure 02: Global RAS-acting Agents Market Revenue (US$ Mn), by Drug Class, 2022
  • Figure 03: Global RAS-acting Agents Market Value Share, by Drug Class, 2022
  • Figure 04: Global RAS-acting Agents Market Revenue (US$ Mn), by Indication, 2022
  • Figure 05: Global RAS-acting Agents Market Value Share, by Indication, 2022
  • Figure 06: Global RAS-acting Agents Market Revenue (US$ Mn), by Distribution Channel, 2022
  • Figure 07: Global RAS-acting Agents Market Value Share, by Distribution Channel, 2022
  • Figure 08: Global RAS-acting Agents Market Value Share, by Region, 2022
  • Figure 09: Global RAS-acting Agents Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 10: Global RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 11: Global RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 12: Global RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 13: Global RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 14: Global RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 15: Global RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 16: Global RAS-acting Agents Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 17: Global RAS-acting Agents Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 18: North America RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 19: North America RAS-acting Agents Market Attractiveness Analysis, by Country, 2017-2031
  • Figure 20: North America RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 21: North America RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 22: North America RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 23: North America RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 24: North America RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 25: North America RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 26: North America RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 27: Europe RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 28: Europe RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 29: Europe RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 30: Europe RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 31: Europe RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 32: Europe RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 33: Europe RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 34: Europe RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 35: Europe RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 36: Asia Pacific RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 37: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 38: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 39: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 40: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 41: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 42: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 43: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 44: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 45: Latin America RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 46: Latin America RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 47: Latin America RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 48: Latin America RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 49: Latin America RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 50: Latin America RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 51: Latin America RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 52: Latin America RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 53: Latin America RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 54: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 55: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 56: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 57: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 58: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 59: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 60: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 61: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 62: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031